Published online before print May 23, 2006, 10.1148/radiol.2401050788
(Radiology 2006;240:82.)
A more recent version of this article appeared on July 1, 2006
Improved Tumor Destruction with Arsenic Trioxide and Radiofrequency Ablation in Three Animal Models1
Andrew Hines-Peralta, MD,
Vikas Sukhatme, MD, PhD,
Meredith Regan, ScD,
Sabina Signoretti, PhD,
Zheng-jun Liu, MD and
S. Nahum Goldberg, MD
1 From the Laboratory for Minimally Invasive Tumor Therapy, Department of Radiology (A.H., Z.j.L., S.N.G.), and Department of Medicine, Renal Division (V.S.), Beth Israel Deaconess Medical Center, 1 Deaconess Rd, WCC 308B, Boston, MA 02215; Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and the Renal Cancer Program of the Dana Farber/Harvard Cancer Center, Boston, Mass (M.R.); Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Mass (S.S.); and Harvard Medical School, Boston, Mass (A.H., V.S., M.R., S.S., Z.j.L., S.N.G.). Received May 9, 2005; revision requested July 7; revision received August 18; final version accepted September 14. Supported by National Cancer Institute Dana Farber/Harvard Cancer Center Renal Cancer SPORE grant 1 P50 CA10194-01.
Address correspondence to S.N.G. (e-mail: sgoldber{at}caregroup.harvard.edu).
View larger version (21K):
[in a new window]
|
Figure 1: Graph illustrates arsenic trioxide dose versus blood flow in intrarenal VX2 tumors and normal kidneys. Preferential dose-dependent reduction in the tumor vasculature blood flow was noted.
|
|
View larger version (29K):
[in a new window]
|
Figure 2: Graph illustrates arsenic trioxide dose versus tumor blood flow in the three tumor models. Increasing the arsenic trioxide dose led to a progressive decrease in blood flow in all tumor models. Differences in the sensitivity of blood flow to arsenic trioxide were observed on a tumor-by-tumor basis. RCC = renal cell carcinoma.
|
|
View larger version (28K):
[in a new window]
|
Figure 3: Graph illustrates tumor coagulation (assessed in terms of coagulation diameter) induced by RF ablation performed 1 hour after arsenic trioxide administration. Dose-dependent curves were demonstrated in all three tumor models, with varying sensitivity to arsenic trioxide dose. RCC = renal cell carcinoma.
|
|
View larger version (68K):
[in a new window]
|
Figure 4: Gross pathologic specimens of RF-induced coagulation in RCC 786-0 tumors treated with RF ablation only (left) and with RF ablation and arsenic trioxide (right). Arrows point to areas where a significantly (P < .05) larger zone of coagulation resulted from RF ablation performed 1 hour after administration of 5 mg/kg arsenic trioxide.
|
|
View larger version (26K):
[in a new window]
|
Figure 5: Graph illustrates tumor blood flow versus RF-induced tumor coagulation diameter. A linear correlation between these variables was demonstrated in all tumor models. RCC = renal cell carcinoma.
|
|
View larger version (32K):
[in a new window]
|
Figure 6: Graph illustrates the effect of the interval between arsenic trioxide administration and RF ablation on the resultant coagulation diameter. The maximal effect was seen 1 hour after the arsenic trioxide administration; this finding suggests a transient nature of the synergistic effect. RCC = renal cell carcinoma.
|
|
View larger version (85K):
[in a new window]
|
Figure 7: Histopathologic sections of RCC 786-0 and VX2 tumors. Similar degrees of tumor vascularity are seen in, A, control agent–treated, and, B, 5 mg/kg arsenic trioxide–treated RCC 786-0 tumors 24 hours after treatment. C, Section of VX2 tumor treated with 5 mg/kg arsenic trioxide also shows numerous patent blood vessels (arrows) 6 hours after arsenic trioxide administration. (Hematoxylin-eosin stain; original magnification, x20.)
|
|
Copyright © 2006 by the Radiological Society of North America.
